EPCAM and neoplasm: Our results indicate that the CEP-LP@S/D co-delivery system could enhance the accumulation of drugs in the tumor tissues and target CSCs via the specific peptide recognition receptors CD133 and EpCAM, which are over-expressed on these cells.